Clofarabine in the Treatment of Elderly Patients with Acute Myeloid Leukemia |
Aleem, Aamer
(Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University)
Anjum, Farhan (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) Algahtani, Farjah (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) Iqbal, Zafar (Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences) Alsaleh, Khalid (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) AlMomen, Abdulkareem (Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences) |
1 | Agura E, Cooper B, Holmes H, et al (2011). Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist, 16, 197-206. DOI |
2 | Burnett AK, Russell NH, Kell J, et al (2010). European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol, 28, 2389-95. DOI ScienceOn |
3 | Faderl S, Verstovsek S, Cortes J, et al (2006). Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 108, 45-51. DOI ScienceOn |
4 | Faderl S, Ravandi F, Huang X, et al (2008). A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 112, 1638-45. DOI ScienceOn |
5 | Godwin JE, Smith SE (2003). Acute myeloid leukemia in the elder patient. Crit Rev Oncol Hematol, 48, 17-26. DOI ScienceOn |
6 | Gupta V, Chun K, Yi QL, et al (2005). Disease biology rather than age is the most important determinant of survival of patients 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer, 103, 2082-90. DOI ScienceOn |
7 | Jeha S, Gandhi V, Chan KW, et al (2004). Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103, 784-89. |
8 | Kantarjian HM, Gandhi V, Kozuch P, et al (2003a). Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol, 21, 1167-73. DOI ScienceOn |
9 | Kantarjian H, Gandhi V, Cortes J, et al (2003b). Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 102, 2379-86. DOI ScienceOn |
10 | Kantarjian H, Ravandi F, O'Brien S, et al (2010). Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 116, 4422-9. DOI ScienceOn |
11 | Kantarjian HM, Erba HP, Claxton D, et al (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol, 28, 549-55. DOI ScienceOn |
12 | Krawczyk J, Ansar N, Swords R, et al (2010). Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematol Oncol, 28, 118-23. |
13 | Leith CP, Kopecky KJ, Godwin J, et al (1997). Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-9. |
14 | Rowe JM, Tallman MS (2010). How I treat acute myeloid leukemia. Blood, 116, 3147-56. DOI ScienceOn |
15 | Malfuson JV, Etienne A, Turlure P, et al (2008). Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica, 93, 1806-13. DOI ScienceOn |
16 | Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM (1992). Secrist JA 3rd. Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem, 35, 397-401. DOI |
17 | Parker WB, Allan PW, Hassan AE, et al (2003). Antitumor activity of 2-fluoro-2-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther, 10, 23-9. DOI ScienceOn |
18 | Styczynski J, Gil L, Derwich K, et al (2009). Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res, 29, 1643-50. |
19 | Tran H, Yang D (2012). Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. Ann Pharmacother, 46, 89-96. DOI ScienceOn |
20 | Tse E, Leung AY, Sim J, et al (2011). Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol, 90, 1277-81. DOI |
21 | Xie KC, Plunkett W (1996). Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-D-arabinofuranosyl) adenine. Cancer Res, 56, 3030-37. |